Antimicrobial Susceptibility Pattern of Clinical Isolates of Escherichia coli and Proteus mirabilis Using Cefepime in Ogbomoso, Nigeria.

The challenge of Cefepime resistance in developing countries is substantial and likely to grow. Emergence of Cefepime-resistant bacteria has increased and management  of this has become a therapeutic challenge. The production of beta lactamases by most bacteria make them to be resistant to beta lactam antibiotics like Cefepime which is common nowadays. Forty clinical isolates of Escherichia coli and Proteus mirabilis from different clinical sites were analyzed between March and August, 2013 using standard bacteriological methods. The aim of this study was the evaluation of the sensitivity of clinical isolates of Escherichia coli and Proteus mirabilis to Cefepime . Their sensitivity against Cefepime (30µg) was determined using disk diffusion method. The isolates were divided into three groups: sensitive, intermediate and resistance based on their sensitivity pattern. The result showed that Escherichia coli had 29.03% sensitivity, 16.13% intermediate and 58.83% resistance while Proteus mirabilis had 22.22% sensitivity, 11.11% intermediate and  66.67%  resistance. The overall susceptibility pattern of the clinical isolates to Cefepime is 27.50% sensitivity, 15.00% intermediate and 57.57% resistance. There was a great Cefepime- resistance among clinical isolates of E. coli and Proteus mirabilis analyzed. The resistance pattern of E. coli and Proteus mirabilis calls for continuous surveillance for Cefepime resistance control.